Company: SNWV
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038937
Chunk: 56

Company: SANUWAVE Health, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 56
---
 available to stockholders65 6,561 (4,621)2,033 Denominator:Weighted average common shares outstanding - Basic8,562 3,153 8,555 3,126 Dilutive effect of warrants363 - - - Dilutive effect of stock options243 - - - Dilutive effect of convertible promissory notes including interest- 547 - 538 Weighted average common shares outstanding - Diluted9,168 3,700 8,555 3,664 Net income (loss) per share:Basic$0.12 $2.08 $(0.54)$0.65 Diluted$0.01 $1.77 $(0.54)$0.55 Diluted net income (loss) per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding that are nominally priced. In June 2024, the Company did not have any dilutive common stock equivalents that were nominally priced. The following securities were excluded from the calculation of diluted net loss per share during the six months ended June 30, 2025 because the result would have been anti-dilutive.Six Months Ended June 30,(in thousands)20252024Common stock options102 42 Common stock purchase warrants2 3,980 Convertible notes payable, including interest- 55 104 4,077 

15.        Concentration of Credit Risk and Limited Suppliers 

The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in the Company’s production. The percentage of purchases from major vendors of the Company that exceeded ten percent of total purchases for the three and six months ended June 30, 2025, and 2024 were as follows:Three Months Ended June 30,Six Months Ended June 30,2025202420252024Purchases:Vendor A19%32%22%20%Vendor B10%-%11%-%

16.        License and Option Agreement

In March 2024, the Company entered into an exclusive license and option agreement (the "Patent License") with a third party licensee in connection with a portfolio of patents related to the field of intravascular shockwave applications. The Company received a one-time payment